Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements

References

• AndrewsL, RalstonS, BlommeE, BarnhartK. A snapshot of biologic drug development: challenges and opportunities. Hum Exp Toxicol. 2015;34(12):1279–1285. doi:10.1177/096032711560359426614816
   PubMed Web of Science ®Google Scholar
• AnselmoAC, GokarnY, MitragotriS. Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2019;18(1):19–40. doi:10.1038/nrd.2018.18330498202
   PubMed Web of Science ®Google Scholar
• AndersonD, LiuR, Anand SubramonyJ, CammackJ. Design control considerations for biologic-device combination products. Adv Drug Deliv Rev. 2017;112:101–105. doi:10.1016/j.addr.2017.01.00328088344
   PubMed Web of Science ®Google Scholar
• ChungSW, Hil-lalTA, ByunY. Strategies for non-invasive delivery of biologics. J Drug Target. 2012;20(6):481–501. doi:10.3109/1061186X.2012.69349922632037
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, food and drug administration staff, and other stakeholders. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Accessed 316, 2020.
   Google Scholar
• RuleS, BrionesJ, SmithR, et al. Preference for rituximab subcutaneous (Sc) and intravenous (Iv) among patients with Cd20+ non-Hodgkin’s lymphoma (Nhl) completing the rasq measure in randomized phase III studies prefmab and mabcute. Value Health. 2014;17(7):A537. doi:10.1016/j.jval.2014.08.1719
   PubMed Web of Science ®Google Scholar
• StonerKL, HarderH, FallowfieldLJ, JenkinsVA. Intravenous versus subcutaneous drug administration. which do patients prefer? A systematic review. Patient. 2014. doi:10.1007/s40271-014-0075-y
   PubMedGoogle Scholar
• FallowfieldL, OsborneS, LangridgeC, MonsonK, KilkerrJ, JenkinsV. Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study. Breast. 2015;24(2):166–170. doi:10.1016/j.breast.2015.01.00225623753
   PubMed Web of Science ®Google Scholar
• JackischC, MullerV, DallP, et al. Subcutaneous trastuzumab for HER2-positive breast cancer - evidence and practical experience in 7 german centers. Geburtshilfe Frauenheilkd. 2015;75(6):566–573. doi:10.1055/s-0035-154617226166837
   PubMed Web of Science ®Google Scholar
• PivotX, GligorovJ, MullerV, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962–970. doi:10.1016/S1470-2045(13)70383-823965225
   PubMed Web of Science ®Google Scholar
• TurnerMR, Balu-IyerSV. Challenges and opportunities for the subcutaneous delivery of therapeutic proteins. J Pharm Sci. 2018;107(5):1247–1260. doi:10.1016/j.xphs.2018.01.00729336981
   PubMed Web of Science ®Google Scholar
• WalshCA, MinnockP, SlatteryC, et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2007;46(7):1148–1152. doi:10.1093/rheumatology/kem07417478471
   PubMed Web of Science ®Google Scholar
• HedayatiE, FracheboudL, SrikantV, GreberD, WallbergS, Linder StragliottoC. Economic benefits of subcutaneous trastuzumab administration: a single institutional study from Karolinska university hospital in Sweden. PLoS One. 2019;14(2):e0211783. doi:10.1371/journal.pone.021178330716137
   PubMed Web of Science ®Google Scholar
• MartinA, LavoieL, GoetghebeurM, SchellenbergR. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23(1):55–60. doi:10.1111/j.1365-3148.2012.01201.x23167310
   PubMed Web of Science ®Google Scholar
• RuleS, CollinsGP, SamantaK. Subcutaneous vs intravenous rituximab in patients with non-hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459–468. doi:10.3111/13696998.2014.91403324720836
   PubMedGoogle Scholar
• NorthRT, HarveyVJ, CoxLC, RyanSN. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. Clinicoecon Outcomes Res. 2015;7:423–430. doi:10.2147/CEOR.S8559926251623
   PubMed Web of Science ®Google Scholar
• PapadmitriouK, TrinhXB, AltintasS, Van DamPA, HuizingMT, TjalmaWA. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives. Facts Views Vis Obgyn. 2015;7(3):176–180.26977267
   PubMed Web of Science ®Google Scholar
• WuN, BhurkeS, ShahN, HarrisonDJ. Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. Clinicoecon Outcomes Res. 2015;7:257–266. doi:10.2147/CEOR.S8393225999750
   PubMedGoogle Scholar
• KyriopoulosD, TsiantouV, PapageorgiouL, TheodoropoulouF, AthanasakisK. Cost-minimization and budget impact analysis of rituximab SC VS rituximab IV for non-hodgkin’s lymphoma (NHLs) in Greece. J Cancer Ther. 2017;8(8):726–734. doi:10.4236/jct.2017.88063
   Google Scholar
• MateosM-V, NahiH, LegiecW, et al. Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA. J Clin Oncol. 2019;37(15_suppl):8005. doi:10.1200/JCO.2019.37.15_suppl.8005
   Web of Science ®Google Scholar
• ChariA, GoldschmidtH, San-MiguelJ, et al. Subcutaneous (SC) daratumumab (DARA) in combination with standard multiple myeloma (MM) treatment regimens: an open-label, multicenter phase 2 study (PLEIADES). Clin Lymphoma Myeloma Leuk. 2019;19(10):e16–e17. doi:10.1016/j.clml.2019.09.023
   Web of Science ®Google Scholar
• UsmaniSZ, NahiH, MateosMV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019;134(8):668–677. doi:10.1182/blood.201900066731270103
   PubMed Web of Science ®Google Scholar
• JinX, ZhuDD, ChenBZ, AshfaqM, GuoXD. Insulin delivery systems combined with microneedle technology. Adv Drug Deliv Rev. 2018;127:119–137. doi:10.1016/j.addr.2018.03.01129604374
   PubMed Web of Science ®Google Scholar
• Hao FengY, Ling LiuJ, ZhuDD, HaoYY, Dong GuoX. Multiscale simulations of drug distributions in polymer dissolvable microneedles. Colloids Surf B Biointerfaces. 2020;189:110844. doi:10.1016/j.colsurfb.2020.11084432044675
   PubMed Web of Science ®Google Scholar
• ChenBZ, ZhangLQ, XiaYY, ZhangXP, GuoXD. A basal-bolus insulin regimen integrated microneedle patch for intraday postprandial glucose control. Sci Adv. 2020;6(28):eaba7260. doi:10.1126/sciadv.aba726032832606
   PubMed Web of Science ®Google Scholar
• BaroletD, BenohanianA. Current trends in needle-free jet injection: an update. Clin Cosmet Investig Dermatol. 2018;11:231–238. doi:10.2147/CCID.S162724
   PubMed Web of Science ®Google Scholar
• Pons-FaudoaFP, BalleriniA, SakamotoJ, GrattoniA. Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomed Microdevices. 2019;21(2):47. doi:10.1007/s10544-019-0389-631104136
   PubMed Web of Science ®Google Scholar
• CollinsDS, Sanchez-FelixM, BadkarAV, MrsnyR. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. J Control Release. 2020;321:475–482. doi:10.1016/j.jconrel.2020.02.03632105759
   PubMed Web of Science ®Google Scholar
• Amgen. Repatha® (evolocumab). Available from: https://www.repatha.com/how-to-start-repatha-injection/. Accessed 1010, 2019.
   Google Scholar
• FrostGI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427–440. doi:10.1517/17425247.4.4.42717683255
   PubMed Web of Science ®Google Scholar
• MathaesR, KoulovA, JoergS, MahlerHC. Subcutaneous injection volume of biopharmaceuticals-pushing the boundaries. J Pharm Sci. 2016;105(8):2255–2259. doi:10.1016/j.xphs.2016.05.02927378678
   PubMed Web of Science ®Google Scholar
• PalmT, SahinE, GandhiR, KhossraviM. The Importance of the Concentration-Temperature-Viscosity Relationship for the Development of Biologics. BioProcess International; 2015.
   Google Scholar
• GaridelP, KuhnAB, SchaferLV, Karow-ZwickAR, BlechM. High-concentration protein formulations: how high is high? Eur J Pharm Biopharm. 2017;119:353–360. doi:10.1016/j.ejpb.2017.06.02928690199
   PubMed Web of Science ®Google Scholar
• JohnsonB, RostovtsevA. High concentration biologic formulations: challenges and solutions. Drug Discov Devel. 2017.
   Google Scholar
• WangW, SinghS, ZengDL, KingK, NemaS. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96(1):1–26. doi:10.1002/jps.2072716998873
   PubMed Web of Science ®Google Scholar
• WarneNW. Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. Eur J Pharm Biopharm. 2011;78(2):208–212. doi:10.1016/j.ejpb.2011.03.00421406226
   PubMed Web of Science ®Google Scholar
• Arecor. Our portfolio; 2020 Available from: http://arecor.com/p^roducts/. Accessed 611, 2020.
   Google Scholar
• Adocia. BIOCHAPERONE® LISPRO; 2020 Available from: https://www.adocia.com/products/biochaperone-ultra-fast-analog-insulin/. Accessed 316, 2020.
   Google Scholar
• ExcelseBio. Your medicine, transformed; 2020 http://www.excelsebio.com/partnering. Accessed 327, 2020.
   Google Scholar
• Xeris Pharmaceuticals. The Xeris solution for conventional formulation limitations. Available from: https://www.xerispharma.com/research-development/technology. Accessed 831, 2020.
   Google Scholar
• Elektrofi. Redefining the delivery of biologics; 2020 Available from: https://www.elektrofi.com/welcome#technology. Accessed 831, 2020.
   Google Scholar
• Lindy Biosciences. Microglassification™. Available from: https://www.lindybio.com/technology. Accessed 831, 2020.
   Google Scholar
• Althea’s new drug formulation technology gains attention from two more top pharmaceutical companies; 2015 Available from: https://ajibio-pharma.com/news-post/altheas-new-drug-formulation-technology-gains-attention-from-two-more-top-pharmaceutical-companies/. Accessed 831, 2020.
   Google Scholar
• Arecor. What we do. Available from: http://arecor.com/technology/. Accessed 831, 2020.
   Google Scholar
• Adocia. BioChaperone®. Available from: https://www.adocia.com/technology/biochaperone-technology-2/. Accessed 831, 2020.
   Google Scholar
• ExcelseBio. EXCELSE™ formulation technology. Available from: http://www.excelsebio.com/technology. Accessed 831, 2020.
   Google Scholar
• Nemera. Safelia® autoinjector designed to be patients and syringes friendly; 2020 Available from: https://www.nemera.net/wp-content/uploads/2014/06/Nemera_LEAFLET-Safelia_revJune2016.pdf. Accessed 831, 2020.
   Google Scholar
• Owen Mumford Pharmaceutical Services. Autoject® Visco - a disposable auto-injector developed for high viscosity formulations; 2020 Available from: https://www.ompharmaservices.com/wp-content/uploads/2019/09/Autoject-Visco-Case-Study-Owen-Mumford.pdf. Accessed 831, 2020.
   Google Scholar
• Owen Mumford Pharmaceutical Services. Autoject® visco; 2020 Available from: https://www.ompharmaservices.com/product-portfolio/autoject-visco/. Accessed 831, 2020.
   Google Scholar
• Ypsomed. YpsoMate 2.25 – the 2-step large volume autoinjector. Available from: https://yds.ypsomed.com/en/injection-systems/auto-injectors/ypsomate-2-25.html. Accessed 831, 2020.
   Google Scholar
• SHL Group. Rotaject® technology; 2020 Available from: https://www.shl.group/products-and-services/rotaject-technology-auto-injector/. Accessed 831, 2020.
   Google Scholar
• Bespak. Vapoursoft® powered auto-injectors; 2020 Available from: https://bespak.com/products/injection-devices/vapoursoft-powered-auto-injectors/. Accessed 831, 2020.
   Google Scholar
• CollierDH, BitmanB, ColesA, LiuL, KumarS, JuddC. A novel electromechanical autoinjector, AutoTouch, for self-injection of etanercept: real-world use and benefits. Postgrad Med. 2017;129(1):118–125. doi:10.1080/00325481.2017.125129127829325
   PubMed Web of Science ®Google Scholar
• Amgen launches the ENBREL Mini™ single-dose prefilled cartridge with AutoTouch™ reusable autoinjector that is ergonomically designed for patients; 2017 Available from: https://www.amgen.com/media/news-releases/2017/11/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-autoinjector-that-is-ergonomically-designed-for-patients/. Accessed 831, 2020.
   Google Scholar
• Oval Medical Technologies. ArQ®-bios subcutaneous (high viscosities and/or high volumes); 2020 Available from: https://www.ovalmedical.com/portfolio/arq-bios/. Accessed 831, 2020.
   Google Scholar
• VeilleuxJC, ShepherdJE. Pressure and stress transients in autoinjector devices. Drug Deliv Transl Res. 2018;8(5):1238–1253. doi:10.1007/s13346-018-0568-730084014
   PubMed Web of Science ®Google Scholar
• Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed; 2020 Available from: https://www.ypsomed.com/fr-FR/dernieres-nouvelles-detail/teva-launches-ajovy-for-the-treatment-of-migraine-with-the-ypsomate-autoinjector-from-ypsomed.html. Accessed 721, 2020.
   Google Scholar
• World Pharmaceutical Frontiers. Latest in injectable technology to enhance biologic development. Available from: http://www.worldpharmaceuticals.net/contractors/world-pharmaceutical-frontiers/latest-in-injectable-technology-to-enhance-biologic-development/. Accessed 415, 2020.
   Google Scholar
• BurtonL, YingW, KulshresthaA, GandhiRB. Challenges in Subcutaneous Product Development of Biologics-Understanding the Impact of Solution Viscosity and Potential Strategies for Enabling SC Delivery of High-Dose And/Or Viscous Biotherapeutics. 2017.
   Google Scholar
• YadiK, MaritanL. Autoinjector platform – identifying new, enhanced device delivery solutions for chronic diseases. Drug Dev Deliv. 2020.
   Google Scholar
• Canè Medical Technology. Infusion pumps. Available from: http://www.infusionpump.it/category/infusion-pumps/. Accessed 831, 2020.
   Google Scholar
• Sensile Medical. Launched products. Available from: https://www.sensile-medical.com/products.html. Accessed 831, 2020.
   Google Scholar
• West Pharma. West SmartDose drug delivery platform. Available from: https://www.westpharma.com/products/self-injection-platforms/smartdose. Accessed 611, 2020.
   Google Scholar
• Alexion. Investor day. Available from: https://ir.alexion.com/static-files/46d4f73c-371a-402d-a271-936d0283b3f6. Accessed 1024, 2019.
   Google Scholar
• Sensile Medical. Innovative micro-infusion pump from gerresheimer subsidiary sensile medical developed and successfully launched for EVER pharma. Available from: https://www.sensile-medical.com/fileadmin/user_upload/News_Events/2019/20190703_Gx_PM_LAUNCH_Mikropumpe_SEN_e.pdf. Accessed 317, 2020.
   Google Scholar
• BD Completes Clinical Trial for BD Libertas™ wearable injector; 2020 Available from: https://www.bd.com/en-us/company/news-and-media/press-releases/bd-completes-clinical-trial-for-bd-libertas-wearable-injector. Accessed 611, 2020.
   Google Scholar
• West Pharma. SmartDose® 3.5 injector. Available from: https://www.westpharma.com/products/self-injection-platforms/smartdose/smartdose-3-5. Accessed 831, 2020.
   Google Scholar
• BD. BD Libertas™ wearable autoinjector. Available from: https://drugdeliverysystems.bd.com/products/self-injection-systems/libertas-wearable-autoinjector. Accessed 318 2020.
   Google Scholar
• Bespak. Lapas®: an innovative patch pump device powered by VapourSoft®. Available from: https://bespak.com/services/innovation/patch-pump-lapas/. Accessed 831, 2020.
   Google Scholar
• Enable Injections. The enable enFuse® on-body platform. Available from: https://enableinjections.com/technology/enfuse-on-body-platform/. Accessed 831, 2020.
   Google Scholar
• Sonceboz. Sonceboz wearable injectors. Available from: https://www.sonceboz.com/wearable-injectors. Accessed 831, 2020.
   Google Scholar
• Sorrel Medical. Platform. Available from: https://www.sorrelmedical.com/platform/. Accessed 831, 2020.
   Google Scholar
• Weibel CDS AG. DrugDeliverySystems. Available from: https://weibelcds.com/products/drug-delivery-systems/. Accessed 831, 2020.
   Google Scholar
• Ypsomed. YpsoDose – the large volume patch injector. Available from: https://yds.ypsomed.com/en/injection-systems/ypsodose.html. Accessed 831, 2020.
   Google Scholar
• AtkinsonWS. Use of hyaluronidase with local anesthesia in ophthalmology; preliminary report. Arch Ophthalmol. 1949;42(5):628–633. doi:10.1001/archopht.1949.00900050638012
   Google Scholar
• Halozyme. Removing traditional limitations on administering therapies: ENHANZE drug delivery technology. Available from: https://www.halozyme.com/enhanze/overview/default.aspx. Accessed 1010, 2019.
   Google Scholar
• LockeKW, ManevalDC, LaBarreMJ. ENHANZE((R)) drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 2019;26(1):98–106. doi:10.1080/10717544.2018.155144230744432
   PubMed Web of Science ®Google Scholar
• PivotX, GligorovJ, MullerV, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25(10):1979–1987. doi:10.1093/annonc/mdu36425070545
   PubMed Web of Science ®Google Scholar
• RummelM, KimTM, AversaF, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28(4):836–842. doi:10.1093/annonc/mdw68528031173
   PubMed Web of Science ®Google Scholar
• PonsfordM, CarneE, KingdonC, et al. Facilitated subcutaneous immunoglobulin (fSCIg) therapy–practical considerations. Clin Exp Immunol. 2015;182(3):302–313. doi:10.1111/cei.1269426288095
   PubMed Web of Science ®Google Scholar
• MorcosPN, ZhangX, McIntyreC, BittnerB, RowellL, HussainZ. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. Int J Clin Pharmacol Ther. 2013;51(7):537–548. doi:10.5414/CP20184723547849
   PubMed Web of Science ®Google Scholar
• MorrowL, MuchmoreDB, LudingtonEA, VaughnDE, HompeschM. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther. 2011;13(10):1039–1045. doi:10.1089/dia.2011.011521714645
   PubMed Web of Science ®Google Scholar
• Halozyme announces janssen receives FDA approval of DARZALEX FASPRO™ utilizing halozyme’s ENHANZE® technology for the treatment of patients with multiple myeloma; 2020 Available from: https://www.halozyme.com/investors/news-releases/news-release-details/2020/Halozyme-Announces-Janssen-Receives-FDA-Approval-Of-DARZALEX-FASPRO-Utilizing-Halozymes-ENHANZE-Technology-For-The-Treatment-Of-Patients-With-Multiple-Myeloma/default.aspx. Accessed 514, 2020.
   Google Scholar
• Halozyme announces janssen receives european marketing authorization for subcutaneous DARZALEX® utilizing halozyme’s ENHANZE® technology for the treatment of patients with multiple myeloma; 2020 Available from: https://www.halozyme.com/investors/news-releases/news-release-details/2020/Halozyme-Announces-Janssen-Receives-European-Marketing-Authorization-For-Subcutaneous-DARZALEX-Utilizing-Halozymes-ENHANZE-Technology-For-The-Treatment-Of-Patients-With-Multiple-Myeloma/default.aspx. Accessed 514, 2020.
   Google Scholar
• Halozyme announces janssen submits new drug application in japan for daratumumab subcutaneous formulation utilizing halozyme’s ENHANZE® technology for patients with multiple myeloma; 2020 Available from: https://www.halozyme.com/investors/news-releases/news-release-details/2020/Halozyme-Announces-Janssen-Submits-New-Drug-Application-In-Japan-For-Daratumumab-Subcutaneous-Formulation-Utilizing-Halozymes-ENHANZE-Technology-For-Patients-With-Multiple-Myeloma/default.aspx. Accessed 514, 2020.
   Google Scholar
• Halozyme announces roche receives FDA approval for Phesgo™ (fixed-dose combination of Perjeta® and Herceptin® for subcutaneous injection) utilizing halozyme’s ENHANZE® technology for the treatment of patients with HER2-positive breast cancer; 2020 Available from: https://www.halozyme.com/investors/news-releases/news-release-details/2020/Halozyme-Announces-Roche-Receives-FDA-Approval-For-Phesgo-Fixed-Dose-Combination-Of-Perjeta-And-Herceptin-For-Subcutaneous-Injection-Utilizing-Halozymes-ENHANZE-Technology-For-The-Treatment-Of-Patients-With-HER2-Positive-Breast-Cancer/default.aspx. Accessed 721, 2020.
   Google Scholar
• Halozyme. Broad range of partnered and proprietary products; 2020 Available from: https://www.halozyme.com/enhanze/pipeline/default.aspx. Accessed 317, 2020.
   Google Scholar
• JansenP. 2014 to 2018: An Update on the State of Wearable Injectors. ONdrugDelivery Magazine; 2018:6–8.
   Google Scholar
• SirkarR. Evaluating Formulation and Device Factors on Subcutaneous Administration. 2019.
   Google Scholar
• JonesGB, CollinsDS, HarrisonMW, ThyagarajapuramNR, WrightJM. Subcutaneous drug delivery: an evolving enterprise. Sci Transl Med. 2017;9(405):eaaf9166. doi:10.1126/scitranslmed.aaf916628855399
   PubMed Web of Science ®Google Scholar
• ZijlstraE, JahnkeJ, FischerA, KapitzaC, ForstT. Impact of injection speed, volume, and site on pain sensation. J Diabetes Sci Technol. 2018;12(1):163–168. doi:10.1177/193229681773512128990437
   PubMedGoogle Scholar
• HamuroL, KijankaG, KindermanF, et al. Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. J Pharm Sci. 2017;106(10):2946–2954. doi:10.1016/j.xphs.2017.05.03028576695
   PubMed Web of Science ®Google Scholar
• DiasC, AbosaleemB, CrispinoC, GaoB, ShaywitzA. Tolerability of high-volume subcutaneous injections of a viscous placebo buffer: a randomized, crossover study in healthy subjects. AAPS PharmSciTech. 2015;16(5):1101–1107. doi:10.1208/s12249-015-0288-y25693652
   PubMed Web of Science ®Google Scholar
• DoughtyDV, ClawsonCZ, LambertW, SubramonyJA. Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery. J Pharm Sci. 2016;105(7):2105–2113. doi:10.1016/j.xphs.2016.04.00927287520
   PubMed Web of Science ®Google Scholar
• BerteauC, Filipe-SantosO, WangT, RojasHE, GrangerC, SchwarzenbachF. Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance. Med Devices (Auckl). 2015;8:473–484. doi:10.2147/MDER.S9101926635489
   PubMedGoogle Scholar
• MercadanteS, FerreraP, GirelliD, Patients’CA. Relatives’ perceptions about intravenous and subcutaneous hydration. J Pain Symptom Manage. 2005;30(4):354–358. doi:10.1016/j.jpainsymman.2005.04.00416256899
   PubMed Web of Science ®Google Scholar
• SchiffM, SaundersonS, MountianI, HartleyP. Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment. Rheumatol Ther. 2017;4(2):445–463. doi:10.1007/s40744-017-0080-428956300
   PubMed Web of Science ®Google Scholar
• BaxterAL, CohenLL, BurtonM, MohammedA, LawsonML. The number of injected same-day preschool vaccines relates to preadolescent needle fear and HPV uptake. Vaccine. 2017;35(33):4213–4219. doi:10.1016/j.vaccine.2017.06.02928647169
   PubMed Web of Science ®Google Scholar
• SokolowskiCJ, GiovannittiJA Jr., BoynesSG. Needle phobia: etiology, adverse consequences, and patient management. Dent Clin North Am. 2010;54(4):731–744. doi:10.1016/j.cden.2010.06.01220831935
   PubMedGoogle Scholar
• GedneyJJ, LoganH. Perceived control and negative affect predict expected and experienced acute clinical pain: a structural modeling analysis. Clin J Pain. 2007;23(1):35–44. doi:10.1097/01.ajp.0000210940.04182.a317277643
   PubMed Web of Science ®Google Scholar
• GelyC, MarinL, GordilloJ, et al. N032 impact of pain due to subcutaneous administration of a biological drug. J Crohns Colitis. 2018;12(supplement_1):S582–S583. doi:10.1093/ecco-jcc/jjx180.1046
   Google Scholar
• CohenS, SamadA, KarisE, et al. Decreased injection site pain associated with phosphate-free etanercept formulation in rheumatoid arthritis or psoriatic arthritis patients: a randomized controlled trial. Rheumatol Ther. 2019;6(2):245–254. doi:10.1007/s40744-019-0152-830915626
   PubMed Web of Science ®Google Scholar
• LaursenT, HansenB, FiskerS. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol. 2006;98(2):218–221. doi:10.1111/j.1742-7843.2006.pto_271.x16445598
   PubMed Web of Science ®Google Scholar
• FrenkenLA, van LierHJ, JordansJG, et al. Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection. Am J Kidney Dis. 1993;22(4):553–556. doi:10.1016/s0272-6386(12)80928-08213795
   PubMed Web of Science ®Google Scholar
• YuAW, LeungCB, LiPK, LuiSF, LaiKN. Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha. Int J Artif Organs. 1998;21(6):341–343. doi:10.1177/0391398898021006129714028
   PubMed Web of Science ®Google Scholar
• NashP, VanhoofJ, HallS, et al. Randomized crossover comparison of injection site pain with 40 mg/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3(2):257–270. doi:10.1007/s40744-016-0041-327747583
   PubMed Web of Science ®Google Scholar
• MartinJR, BeegleNL, ZhuY, HanischEM. Subcutaneous administration of bortezomib: a pilot survey of oncology nurses. J Adv Pract Oncol. 2015;6(4):308–318. doi:10.6004/jadpro.2015.6.4.226705492
   PubMedGoogle Scholar
• Sanchez-FelixM, BurkeM, ChenHH, PattersonC, MittalS. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge. Adv Drug Deliv Rev. 2020;167:66–77. doi:10.1016/j.addr.2020.05.00932473188
   PubMed Web of Science ®Google Scholar